African-American Women With Prior Benign Disease Diagnosis at Higher TNBC Risk

Share this content:
Among African-American women, the 10-year probability estimate for the development of TNBC was 0.56% compared to 0.25% among Caucasian women.
Among African-American women, the 10-year probability estimate for the development of TNBC was 0.56% compared to 0.25% among Caucasian women.

African-American identity among women with a prior diagnosis of benign breast disease (BBD) is a significant risk factor for triple-negative breast cancer (TNBC), according to a study published in JAMA Oncology.1

Researchers conducted a retrospective analysis of data to examine whether African-American identity was associated with TNBC among women with a prior diagnosis of BBD.

Researchers evaluated data from 2588 African-American women and 3566 white American women between the ages of 40 and 70 years who had a biopsy-proven diagnosis of BBD. Care was found to be delivered “equitably” between the 2 groups of women based on case management, follow-up and treatment outcomes.

Among African-American women, the 10-year probability estimate for the development of TNBC was 0.56% compared to 0.25% among Caucasian women.

A total of 103 African-American women (4.1%) and 143 Caucasian women (4%) had developed subsequent breast cancers, with over three-fourths of these cancers between the 2 groups being ductal carcinoma in situ or stage I.

RELATED: Larger Social Networks Linked With Better Breast Cancer Survival

Sixteen of 66 African-American women with subsequent invasive breast cancer and complete biomarker data had developed TNBC compared to 7 of 94 Caucasian women.

“This study is the largest analysis to date of TNBC in the context of racial/ethnic identity and BBD as risk factors,” the authors noted. “This finding suggests that African-American identity is associated with inherent susceptibility for TNBC pathogenetic pathways.”

Reference

  1. Newman LA, Stark A, Chitale D, et al. Association between benign breast disease in African American and white American women and subsequent triple-negative breast cancer. JAMA Oncol. 2016 Dec 22. doi:10.1001/jamaoncol.2016.5598 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters